Malaria

Manson's Tropical Diseases: Twenty-Third Edition

Volumn , Issue , 2013, Pages 532-600

  White, Nicholas J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942873008     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-5101-2.00044-3     Document Type: Chapter

References (46)

1. Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013, 56(3):383-397.
2. Sutherland CJ, Tanomsing N, Nolder D, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis 2010, 201:1544-1550.
3. White NJ Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011, 10:e297.
4. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011, 480:534-537.
5. Bousema T, Drakeley C Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011, 24:377-410.
6. Roper C, Pearce R, Nair S, et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004, 305:1124.
7. World Health Organization World Malaria Report Online. Available:. http://www.who.int/malaria/world_malaria_report_2011/en/.
8. Hay SI, Okiro EA, Gething PW, et al. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 2010, 7:e1000290.
9. Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008, 47:151-157.
10. Taylor SM, Parobek CM, Fairhurst RM Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:457-468.
11. Williams TN Balancing act: haemoglobinopathies and malaria. Lancet Infect Dis 2012, 12:427-428.
12. Louicharoen C, Patin E, Paul R, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science 2009, 326:1546-1549.
13. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med 2012, 9:e1001297.
14. Tilley L, Dixon MW, Kirk K The Plasmodium falciparum-infected red blood cell. Int J Biochem Cell Biol 2011, 43:839-842.
15. McGuire W, Hill AV, Allsopp CE, et al. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994, 371:508-510.
16. Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Path 1999, 155:395-410.
17. Beare NA, Taylor TE, Harding SP, et al. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 2000, 75:790-797.
18. Hanson J, Lam SW, Mahanta KC, et al. Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. J Infect Dis 2012, 206:571-579.
19. Juillerat A, Igonet S, Vigan-Womas I, et al. Biochemical and biophysical characterization of DBL1alpha1-varO, the rosetting domain of PfEMP1 from the VarO line of Plasmodium falciparum. Mol Biochem Parasitol 2010, 170:84-92.
20. Dorovini-Zis K, Schmidt K, Huynh H, et al. The neuropathology of fatal cerebral malaria in Malawian children. Am J Pathol 2011, 178:2146-2158.
21. Potchen MJ, Kampondeni SD, Seydel KB, et al. Acute brain MRI findings in 120 Malawian children with cerebral malaria: new insights into an ancient disease. Am J Neuroradiol 2012, 33:1740-1746.
22. Maitland K, Kiguli S, Opoka RO, et al. FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011, 364:2483-2495.
23. Buffet PA, Safeukui I, Deplaine G, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011, 117:381-392.
24. Wilson ML Malaria rapid diagnostic tests. Clin Infect Dis 2012, 54:1637-1641.
25. Douglas NM, Nosten F, Ashley EA, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: Risk factors and effect of antimalarial kinetics. Clin Infect Dis 2011, 52:612-620.
26. McGready R, Lee S, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012, 12(5):388-396.
27. World Health Organization Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000, 94(Suppl 1):S1-S90.
28. Idro R, Marsh K, John CC, et al. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res 2010, 68:267-274.
29. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-467.
30. Laufer MK, Takala-Harrison S, Dzinjalamala FK, et al. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 2010, 202:801-808.
31. Zwang J, Dorsey G, Djimdé A, et al. Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa. Malar J 2012, 11:260e.
32. Dondorp AM, Fanello CE, Hendriksen ICE, et al. for the AQUAMAT group. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010, 376:1647-1657.
33. Gomes MF, Faiz MA, Gyapong JO, et al. Study 13 Research Group. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009, 373:557-566.
34. World Health Organization The treatment of malaria 2010, WHO, Geneva.
35. Croft SL, Duparc S, Arbe-Barnes SJ, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J 2012, 11:e270.
36. Keating GM Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs 2012, 72:937-961.
37. Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006, 367:133-143.
38. Cairns M, Roca-Feltrer A, Garske T, et al. Estimating the potential public health impact of seasonal malaria chemoprevention in African children 2012, 3. Nat Commun.
39. RTS,S Clinical Trials Partnership A Phase 3 Trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367(24):2284-2295.
40. Gething PW, Patil AP, Smith DL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011, 10:378.
41. Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012, 6(9):e1814.
42. Taylor SM, Parobek CM, Fairhurst RM Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:457-468.
43. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med 2012, 9:e1001297.
44. Wilson ML Malaria rapid diagnostic tests. Clin Infect Dis 2012, 54:1637-1641.
45. Croft SL, Duparc S, Arbe-Barnes SJ, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J 2012, 11:e270.
46. Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012, 6(9):e1814.